THONBURI HEALTHCARE GROUP |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.25 THB | 0.00% |
|
-2.48% | -27.65% |
| Apr. 18 | Thonburi Healthcare Group Public Company Limited Announces Board Committee Changes | CI |
| Apr. 18 | Thonburi Healthcare Group Public Company Limited Announces Board Changes | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an expected P/E ratio at 39.51 and 33.55 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 3.59 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Most analysts recommend that the stock should be sold or reduced.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -27.65% | 903M | - | ||
| -18.46% | 16.57B | B+ | ||
| +4.50% | 12.51B | B | ||
| +4.31% | 11.69B | B+ | ||
| +5.36% | 10.36B | B+ | ||
| +24.72% | 8.38B | B | ||
| -2.64% | 7.75B | A- | ||
| +20.04% | 7.16B | D | ||
| +4.17% | 6.6B | B- | ||
| +46.90% | 4.54B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- THG Stock
- Ratings Thonburi Healthcare Group
